国人牙直丝托槽定位值的测量研究

为建立适合国人牙直丝托槽定位值,选择符合Ａｎｄｒｅｗ ｓ 正常牙合成年人６０ 例,男女各３０ 例,１８～２１ 岁,平均１９．２ 岁,均具有协调的面部比例,未接受正畸治疗。弓丝平面定义为大多数牙临床牙冠中点所在的平面,用游标卡尺测量每一牙齿切缘（或牙合缘）,至弓丝平面的距离,为直丝托槽应就位的位置。结果显示,托槽并非全部位于每个牙的临床牙冠中点,在上颌双尖牙区,托槽位于临床牙冠中点龈方０．５ｍ ｍ 处,第二磨牙托槽位于临床牙冠中点偏牙合方０．５ｍ ｍ ～１．０ｍ ｍ 处,在下颌尖牙及第一、二磨牙处,托槽位于临床牙冠中点偏牙合方０．５ｍ ｍ 处。表明本研究建立的托槽定位值适合于国人,且可明显提高直丝托槽垂直置入精确度     

雷公藤多甙对肾性蛋白尿患者外周血单个核细胞作用的研究

通过琼脂糖凝胶电泳, Ｈ Ｅ 染色和流式细胞仪检测用雷公藤多甙治疗肾性蛋白尿患者 ２ 周后外周血单个核细胞的凋亡情况。经治疗后患者外周血单个核细胞在形态上出现典型的细胞核固缩、碎裂,琼脂糖凝胶电泳显现特征性的“梯状”带,流式细胞仪上出现亚二倍体峰。提示雷公藤多甙能诱导肾性蛋白尿患者外周血单个核细胞的凋亡。     

骨肉瘤细胞核因子кB免疫组化研究

细胞核因子ＮＦ－кＢ在肿瘤血管生成中可能具有核心调节作用,本文选择８０例有随访结果的骨肉瘤,应用免疫组化方法检测 ＮＦ－кＢ ｐ６５亚单位以及血管内皮细胞生长因子（ＶＥＧＦ）的表达,同时观察肿瘤内微血管密度（ＭＶＤ）,旨在探讨 ＮＦ－кＢ表达与骨肉瘤血管生成的关系。结果：８０例骨肉瘤中 ４８例 ＮＦ－кＢ ｐ６５阳性,阳性产物主要定位于肿瘤细胞浆。ＮＦ－кＢ表达与ＶＥＧＦ表达和ＭＶＤ呈显著正相关,而且ＮＦ－кＢ阳性组病人存活时间显著低于阴性组。该结果表明：①ＮＦ－кＢ ｐ６５是骨肉瘤相关的一种癌蛋白,在骨肉瘤的发生和发展中发挥重要的作用;②ＮＦ－кＢ对ＶＥＧＦ可能有正向调节作用,进而影响骨肉瘤血管生成;③ＮＦ－кＢ　对肿瘤血管生成的作用,可能是影响骨肉瘤预后的主要原因之一。     

蓝舌病毒HbC株的增殖和血清学特点

研究蓝舌病毒中国湖北分离株（ＢＴＶ ＨｂＣ株）在Ｖｅｒｏ和ＢＨＫ ２１两种细胞上的增殖特点以及与标准病毒株（ＢＴＶ １０）的血清学关系。发现ＢＴＶ ＨｂＣ和ＢＴＶ １０感染Ｖｅｒｏ和ＢＨＫ ２１单层细胞后,２４～３０ｈ病毒滴度可达到最高值。用ＢＴＶ ＨｂＣ免疫家兔,其抗血清在琼脂双扩试验中能与ＢＴＶ １０抗原病毒呈强阳性反应而与轮状病毒、风疹病毒、柯萨奇病毒、流感病毒等呈阴性反应。     

Inhibitory Effect of recombinant FN polypeptide CH50 on the metastasis and tumor growth

Immunotherapycouldremoveresidualtumorcellsbyenhancinganti-tumorfunc-tionofimmunesystemaftersurgicalre-movaloftumor.ltisatime-consumingtofullyactivateimmunece11sandformstrongcytotoxicityontumorcellsinvivo.ltisim-perativetofindawaytoactivateanti-tumoractivityofimmunecellsquick1yenoughinvivosothattheresidualtumorcellscouldbeattackedasearlyaspossible.CH5oisabifunctiona1-domainrecombinantpolypep-tidewhichcontainsCellIandHepIdo-mainsofhumanfibronectin(FN)andisabIetoexpressinE-coli[lj.Thispolypep-…     

抗A1试剂血清的研制

目的 :ABO亚型在临床输血中经常造成错定血型及输血反应 ,因而研制抗A1试剂血清是解决ABO亚型鉴定的主要途径。方法 :采用血型血清学特异性抗原抗体吸收实验。结果 :经大量反复实验 ,研制出特异性强 ,效价符合要求的抗A1试剂血清。结论 :抗A1血清是鉴定A亚型的专用试剂血清 ,对临床鉴定ABO亚型及安全输血有实用意义。     

蓖麻油餐用于晚期妊娠引产118例分析

目的：观察蓖麻油餐用于晚期妊娠引产的疗效。方法：随机选择１１８例服用蓖麻油餐引产与同期１０６例催产素引产作对照,观察引产效果、产程、产后出血及新生儿评分。结果：观察组引产效率明显高于对照组（Ｐ＜００５）,剖宫产率明显低于对照组（Ｐ＜００５）,两组的产后出血和新生儿阿氏评分无显著性差异（Ｐ＞００５）。结论：蓖麻油引产优于催产素引产。     

类风湿性关节炎患者血清IL-6、TNF水平变化及其意义探讨

采用细胞生物学方法测定类风湿性关节炎（ Ｒ Ａ）１４ 例血清 Ｉ Ｌ－ ６ 、 Ｔ Ｎ Ｆ 水平,均显著高于正常对照组（ Ｐ＜ ０ ．００１） 。相关分析显示 Ｉ Ｌ－ ６ 与 Ｔ Ｎ Ｆ 水平变化呈正相关（ Ｐ＜ ０ ．０１） , Ｉ Ｌ－ ６ 、 Ｔ Ｎ Ｆ 与血沉亦呈正相关（ Ｐ＜０ ．０５） 。认为, Ｉ Ｌ－ ６ 、 Ｔ Ｎ Ｆ 参与 Ｒ Ａ 的发病,两者在致病中有协同相同;其水平变化与 Ｒ Ａ 的活动性及血沉相关。     

Drug policy in China: pharmaceutical distribution in rural areas

In 1978, China decided to reform its economy and since then has gradually opened up to the world. The economy has grown rapidly at an average of 9.8% per year from 1978 to 1994. Medical expenditure, especially for drugs, has grown even more rapidly. The increase in medical expenditure can be attributed to changing disease patterns, a higher proportion of older people in the population and fee-for-service incentives for hospitals. Due to the changing economic system and higher cost of health care, the Chinese government has reformed its health care system, including its health and drug policy. The drug policy reform has led to more comprehensive policy elements, including registration, production, distribution, utilization and administration. As a part of drug policy reform, the drug distribution network has also been changed, from a centrally controlled supply system (push system) to a market-oriented demand system (pull system). Hospitals can now purchase drugs directly from drug companies, factories and retailers, leading to increased price competition. Patients have easier access to drugs as more drugs are available on the market. At the same time, this has also entailed negative effects. The old drug administrative system is not suitable for the new drug distribution network. It is easy for people to get drugs on the market and this can lead to overuse and misuse. Marketing factors have influenced drug distribution so strongly that there is a risk of fake or low quality drugs being distributed. The government has taken some measures to fight these negative effects. This paper describes the drug policy reform in China, particularly the distribution of drugs to health care facilities.     

Evaluation of the purity of a purified, inactivated hepatitis A vaccine (VAQTA).

Manufacture of VAQTA, an inactivated hepatitis A virus vaccine, includes extensive purification of the intact virus particle to remove endogenous components from the host cell culture lysate as well as compounds introduced in the upstream purification process. Analysis of the final purified hepatitis A virus product by SDS-PAGE prior to inactivation shows that greater than 95% of the protein in the preparation is found in four protein bands, which have been confirmed to be hepatitis A virus capsid proteins VP0, VP1, VP2 and VP3 based on Western blot and mass spectrometry analyses. Validation of the manufacturing process and direct analysis of the final product were used to demonstrate that no other specific host cell-derived components are detected and that process residuals are all below the limits of detection of the assays used. Establishment of a rigorous standard of high purity for this product was pursued to minimize the impact of impurities during clinical development of this product and will facilitate the incorporation of this product into combination vaccines.